ArticleAnnals of medicine and surgery (2012)2026
Adenovirus E1A protein sensitizes chemotherapy-resistant tumors to cisplatin.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin resistance remains a critical obstacle in surgical oncology, with treatment failure exceeding 60% in recurrent solid tumors. The adenovirus type 5 early region 1A (E1A) protein demonstrates remarkable chemosensitization through p53-dependent and p53-independent pathways, achieving a 10-fold enhancement in cisplatin sensitivity in resistant cell lines. Clinical trials combining E1A-expressing oncolytic adenoviruses with cisplatin show response rates of 63% compared to 30-40% for chemotherapy alone. E1A restores apoptotic responses through p19ARF/p53 signaling, nuclear factor-kappaB inhibition, and CtBP corepressor interactions. Integration with surgical cytoreduction offers promise for neoadjuvant tumor downstaging and adjuvant micrometastatic elimination. Despite immunogenicity challenges, E1A-based viral therapeutics represent a mechanistically validated approach warranting inclusion in multimodal treatment strategies for chemotherapy-resistant cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.